UPCC 06618: Phase II Study of Adjuvant Nivolumab in Patients with Resected Stage IIB/IIC Melanoma

99 years or below
All
Phase 2
1 Location

Brief description of study

The purpose of this study is to determine how effective and safe the investigational drug nivolumab is for patients who have newly diagnosed cutaneous melanoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD
  • Age: 99 years or below
  • Gender: All
Updated on 12 Sep 2018. Study ID: 830162

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.